文献速递乳腺癌

年轻女性乳腺癌与预后:增殖标志物有多重要?

Breast cancer in young women and prognosis: How important are proliferation markers?
PubMed 文献 · Eur J Cancer · 2017-08-29

基于人群队列研究,纳入504例<40岁和383例≥40岁女性乳腺癌患者,分析增殖标志物表达与年龄、亚型及远期预后的关系。年轻女性管腔型肿瘤Ki-67和细胞周期蛋白表达显著更高,但增殖标志物仅在该亚型内有预后价值;Ki-67仅在年轻管腔型PR+肿瘤中有预后意义,细胞周期蛋白E1高表达在<40岁管腔型PR-肿瘤中与更好的DDFS相关(HR 0.47 [0.24-0.92])。

要点

  • 年轻女性管腔型肿瘤的Ki-67和细胞周期蛋白表达显著高于中年女性。
  • 增殖标志物仅在管腔型亚型内有预后价值,Ki-67仅在年轻管腔型PR+肿瘤中有预后意义。
  • 细胞周期蛋白E1高表达在<40岁管腔型PR-肿瘤中与更好DDFS相关(HR 0.47 [0.24-0.92])。

核心结论

  • 年轻女性增殖标志物高表达对预后影响不显著。
  • Ki-67仅在年轻管腔型PR+肿瘤亚组中有预后价值。
  • 除亚型外唯一增加预后价值的细胞周期蛋白是细胞周期蛋白E1。
  • 年龄仅在管腔型B PR+肿瘤中是独立预后因素(HR 2.35 [1.22-4.50])。

研究设计与样本

  • 基于人群队列研究,纳入504例<40岁和383例≥40岁女性乳腺癌患者。
  • 从医疗记录收集患者特征、治疗和随访信息,制作组织芯片分析雌激素受体、孕激素受体(PR)、Her2、Ki-67和细胞周期蛋白表达。
  • 研究终点为远处无病生存期(DDFS)。

主要发现

  • 年轻女性管腔型肿瘤的Ki-67和细胞周期蛋白表达显著更高。
  • 增殖标志物仅在该亚型内有预后价值,Ki-67仅在年轻管腔型PR+肿瘤中有预后意义。
  • Ki-67的最佳截断值因年龄而异。
  • 细胞周期蛋白E1高表达在<40岁管腔型PR-肿瘤中与更好DDFS相关(HR 0.47 [0.24-0.92])。
  • 年龄<40岁仅在管腔型B PR+肿瘤中是DDFS的独立危险因素(HR 2.35 [1.22-4.50])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Compared to middle-aged women, young women with breast cancer have a higher risk of systemic disease. We studied expression of proliferation markers in relation to age and subtype and their association with long-term prognosis. METHODS: Distant disease-free survival (DDFS) was studied in 504 women aged <40 years and 383 women aged ≥40 years from a population-based cohort. Information on patient characteristics, treatment and follow-up was collected from medical records. Tissue microarrays were produced for analysis of oestrogen receptor, progesterone receptor (PR), Her2, Ki-67 and cyclins. RESULTS: Young women with luminal tumours had significantly higher expression of Ki-67 and cyclins. Proliferation markers were prognostic only within this subtype. Ki-67 was a prognostic indicator only in young women with luminal PR+ tumours. The optimal cut-off for Ki-67 varied by age. High expression of cyclin E1 conferred a better DDFS in women aged <40 years with luminal PR- tumours (hazard ratio [HR] 0.47 [0.24-0.92]). Age <40 years was an independent risk factor of DDFS exclusively in women with luminal B PR+ tumours (HR 2.35 [1.22-4.50]). Young women with luminal B PR- tumours expressing low cyclin E1 had a six-fold risk of distant disease compared with luminal A (HR 6.21 [2.17-17.6]). CONCLUSIONS: The higher expression of proliferation markers in young women does not have a strong impact on prognosis. Ki-67 is only prognostic in the subgroup of young women with luminal PR+ tumours. The only cyclin adding prognostic value beyond subtype is cyclin E1. Age is an independent prognostic factor only in women with luminal B PR+ tumours.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fredholm H, Magnusson K, Lindström LS, et al. Breast cancer in young women and prognosis: How important are proliferation markers? Eur J Cancer. 2017. PMID: 28844016. doi:10.1016/j.ejca.2017.07.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。